[1] |
FORNER A, LLOVET JM. BRUIX J. Hepatocellular carcinoma[J]. Curr Opin Gastroenterol, 2006, 10(2): 339-351. DOI: 10.1016/S0140-6736(18)30010-2.
|
[2] |
WANG S, WU QW, LI XK, et al. Interpretation of guidelines for the diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(5): 996-999. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
王姗, 吴庆旺, 李小科, 等. 《原发性肝癌诊疗规范(2019年版)》解读[J]. 临床肝胆病杂志, 2020, 36(5): 996-999. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
|
[3] |
YUAN SX, ZHOU WP. Progress and hot spots of comprehensive treatment for primary liver cancer[J]. Chin J Dig Surg, 2021, 20(2): 163-170. DOI: 10.3760/cma.j.cn115610-20201211-00776.
袁声贤, 周伟平. 原发性肝癌综合治疗的进展和热点[J]. 中华消化外科杂志, 2021, 20(2): 163-170. DOI: 10.3760/cma.j.cn115610-20201211-00776.
|
[4] |
WU M, LIU Z, ZHANG A, et al. Associated measurement of fucosylated levels of AFP, DCP, and GPC3 for early diagnosis in hepatocellular carcinoma[J]. Int J Biol Markers, 2019, 34(1): 20-26. DOI: 10.1177/1724600818812472.
|
[5] |
BAI DS, ZHANG C, CHEN P, et al. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma[J]. Sci Rep, 2017, 7(1): 12870. DOI: 10.1038/s41598-017-12834-1.
|
[6] |
YANG X, ZHANG Y, ZHANG L, et al. Silencing alpha-fetoprotein expression induces growth arrest and apoptosis in human hepatocellular cancer cell[J]. Cancer Lett, 2008, 271(2): 281-293. DOI: 10.1016/j.canlet.2008.06.017.
|
[7] |
CHEN SF, ZHAO LJ. Research progress on mechanisms for occurrence of liver cancer and its treatment status[J]. Chin J Gen Surg, 2018, 27(7): 910-923. DOI: 10.3978/j.issn.1005-6947.2018.07.016.
陈世发, 赵礼金. 肝癌发生发展机制的研究进展及其治疗现状[J]. 中国普通外科杂志, 2018, 27(7): 910-923. DOI: 10.3978/j.issn.1005-6947.2018.07.016.
|
[8] |
ZHANG J, CHEN G, ZHANG P, et al. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis[J]. PLoS One, 2020, 15(2): e0228857. DOI: 10.1371/journal.pone.0228857.
|
[9] |
DING X, YANG LY, HUANG GW, et al. Role of AFP mRNA expression in peripheral blood as a predictor for postsurgical recurrence of hepatocellular carcinoma: A systematic review and meta-analysis[J]. World J Gastroenterol, 2005, 11(17): 2656-2661. DOI: 10.3748/wjg.v11.i17.2656.
|
[10] |
MUEHLEMANN M, MILLER KD, DAUPHINEE M, et al. Review of growth inhibitory peptide as a biotherapeutic agent for tumor growth, adhesion, and metastasis[J]. Cancer Metastasis Rev, 2005, 24(3): 441-467. DOI: 10.1007/s10555-005-5135-2.
|
[11] |
LI M, LI H, LI C, et al. Alpha-fetoprotein: A new member of intracellular signal molecules in regulation of the PI3K/AKT signaling in human hepatoma cell lines[J]. Int J Cancer, 2011, 128(3): 524-532. DOI: 10.1002/ijc.25373.
|
[12] |
ZHENG L, GONG W, LIANG P, et al. Effects of AFP-activated PI3K/Akt signaling pathway on cell proliferation of liver cancer[J]. Tumour Biol, 2014, 35(5): 4095-4099. DOI: 10.1007/s13277-013-1535-z.
|
[13] |
ZHANG CS, ZHANG XZ, HAN ZM, et al. Silence of cytoskeleton-associated protein 2 represses cell proliferation and migration and promotes apoptosis in liver cancer cell lines[J]. J Cent South Univ(Med Sci), 2020, 45(4): 365-371. DOI: 10.11817/j.issn.1672-7347.2020.180798.
张昌生, 张学贞, 韩宗明, 等. 沉默细胞骨架相关蛋白2抑制肝癌细胞增殖和迁移并促进细胞凋亡[J]. 中南大学学报(医学版), 2020, 45(4): 365-371. DOI: 10.11817/j.issn.1672-7347.2020.180798.
|
[14] |
ZHU MY, FU SG, LI MS, et al. Inhibited the activity of PTEN by α-Fetoprotein caused resistance to all trans retinoic acid of hepatoma cells[J]. Prog Biochem Biophys, 2011, 38(3): 227-238. DOI: 10.3724/SP.J.1206.2010.00546.
朱明月, 符史干, 李孟森, 等. 甲胎蛋白抑制PTEN活性导致肝癌细胞耐受ATRA诱导的凋亡[J]. 生物化学与生物物理进展, 2011, 38(3): 227-238. DOI: 10.3724/SP.J.1206.2010.00546.
|
[15] |
BRABLETZ T, KALLURI R, NIETO MA, et al. EMT in cancer[J]. Nat Rev Cancer, 2018, 18(2): 128-134. DOI: 10.1038/nrc.2017.118.
|
[16] |
THIERY JP. Epithelial-mesenchymal transitions in tumour progression[J]. Nat Rev Cancer, 2002, 2(6): 442-454. DOI: 10.1038/nrc822.
|
[17] |
WANG Y, GUO T, LI JH, et al. Biological function and regulatory mechanism of epithelial- mesenchymal transition-related long non-coding RNAs in liver cancer[J]. J Clin Hepatol, 2019, 35(3): 656-660. DOI: 10.3969/j.issn.1001-5256.2019.03.046.
王元, 郭涛, 李靖华, 等. 上皮-间质转化相关长链非编码RNA在肝癌中的生物学功能及调控机制[J]. 临床肝胆病杂志, 2019, 35(3): 656-660. DOI: 10.3969/j.issn.1001-5256.2019.03.046.
|
[18] |
CHAMBERS AF, GROOM AC, MACDONALD IC. Dissemination and growth of cancer cells in metastatic sites[J]. Nat Rev Cancer, 2002, 2(8): 563-572. DOI: 10.1038/nrc865.
|
[19] |
SA R, SONG H, WEI M, et al. MiR-616 plays oncogenic role in hepatocellular carcinoma progression through suppressing PTEN expression and activating PI3K/AKT pathway[J]. Artif Cells Nanomed Biotechnol, 2020, 48(1): 728-734. DOI: 10.1080/21691401.2019.1596928.
|
[20] |
THAPA N, CHEN M, HORN HT, et al. Phosphatidylinositol-3-OH kinase signalling is spatially organized at endosomal compartments by microtubule-associated protein 4[J]. Nat Cell Biol, 2020, 22(11): 1357-1370. DOI: 10.1038/s41556-020-00596-4.
|
[21] |
GOLOB-SCHWARZL N, KRASSNIG S, TOEGLHOFER AM, et al. New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors[J]. Eur J Cancer, 2017, 83: 56-70. DOI: 10.1016/j.ejca.2017.06.003.
|
[22] |
LEE S, CHOI EJ, CHO EJ, et al. Inhibition of PI3K/Akt signaling suppresses epithelial-to-mesenchymal transition in hepatocellular carcinoma through the Snail/GSK-3/beta-catenin pathway[J]. Clin Mol Hepatol, 2020, 26(4): 529-539. DOI: 10.3350/cmh.2019.0056n.
|